Rome IV - Fecal Incontinence

Why use it

Fecal incontinence is a taboo symptom that patients rarely volunteer. Applying Rome IV C7 criteria enables a structured, positive diagnosis based on symptom pattern and mechanism, guides appropriate anorectal physiological investigations (anorectal manometry, endoanal ultrasound, defecography), directs treatment toward the dominant mechanism (pelvic floor rehabilitation for hypotonic sphincter; loperamide for diarrhea-associated; biofeedback for sensory impairment), and avoids misclassifying major structural causes as functional. It also provides a validated, internationally accepted framework for research and clinical audit.

About

The Rome IV criteria for Fecal Incontinence (category C7) were established by the Rome Foundation Anorectal Disorders Committee and published in Gastroenterology in 2016. Fecal incontinence is defined as the recurrent uncontrolled passage of fecal material in an individual with a developmental age of at least 4 years. Rome IV distinguishes functional fecal incontinence — arising from abnormal functioning of normally innervated, structurally intact muscles; minor sphincter abnormalities; disordered bowel habits; or psychological causes — from organic fecal incontinence caused by major neurological lesions, significant sphincter disruption from surgery or obstetric injury, or rectal wall abnormalities. The criteria require symptoms to have been present for at least 3 months. Fecal incontinence affects 2–20% of community-dwelling adults, with higher prevalence in women, older adults, and nursing home residents. It is profoundly underreported — studies suggest fewer than 30% of affected patients disclose symptoms to a healthcare provider. The condition is associated with severe quality-of-life impairment, social isolation, depression, and work disability. Rome IV C7 provides a positive diagnostic framework that separates functional from structural etiologies and guides appropriate investigation and management.

When to use

• Adults (developmental age ≥4 years) with recurrent uncontrolled passage of fecal material
• After history and examination have assessed for major structural or neurological causes (major sphincter disruption, spinal cord lesion, rectal prolapse, rectal cancer)
• Guiding the selection of anorectal investigations — anorectal manometry, endoanal ultrasound, pudendal nerve terminal motor latency, defecography
• Classifying mechanism (passive incontinence vs. urge incontinence vs. post-defecatory soiling) to direct targeted treatment
• Distinguishing functional fecal incontinence from organic causes requiring surgery
• Assessing response to treatment (biofeedback, loperamide, sacral nerve stimulation) in clinical practice and trials
• Geriatric and nursing home settings where fecal incontinence is prevalent and underdiagnosed
• NOT applicable when major neurological lesion (brain, spinal cord, sacral nerve roots) is the primary cause of sphincter denervation, or when major sphincter defect from obstetric injury or surgery is confirmed as the sole cause

Formula

Pearls & pitfalls

• Fecal incontinence is classified by mechanism: passive incontinence (leakage without awareness — IAS dysfunction), urge incontinence (inability to defer despite warning — EAS weakness), and post-defecatory soiling (leakage after defecation — incomplete evacuation). Each requires different treatment.
• The Rome IV definition requires developmental age ≥4 years — this is important in cognitively impaired adults, where "voluntary control" must be benchmarked against the individual's developmental capacity.
• Rectal urgency with incontinence does NOT always indicate a structural sphincter defect — it may reflect rectal hypersensitivity (low rectal compliance, lowered sensory threshold) or inflammatory bowel disease; always consider these alternatives.
• Up to 50% of women with obstetric sphincter injuries remain continent for years and develop incontinence only after menopause when age-related sphincter atrophy reduces functional reserve. Do not assume a previous OASI is the sole cause if symptoms onset is decades later.
• Comorbid constipation with overflow (fecal impaction with seepage) presents as fecal incontinence — always assess for impaction, especially in elderly and cognitively impaired patients. This is NOT functional fecal incontinence under Rome IV.
• Biofeedback is the most evidence-based treatment for functional fecal incontinence — it is superior to sham treatment in RCTs and effective for both urge and passive incontinence by training the sensorimotor axis.
• The Fecal Incontinence Severity Index (FISI) and St. Mark's Incontinence Score are validated severity instruments that should accompany the Rome IV diagnosis for clinical documentation and treatment monitoring.
• Sacral nerve stimulation (SNS / sacral neuromodulation) is now the gold standard for refractory functional fecal incontinence with intact or minor sphincter defects — approval by FDA and NICE; effective in 70–80% of appropriately selected patients.
• Loperamide is significantly underused in the management of diarrhea-associated fecal incontinence — it increases sphincter resting tone, reduces stool frequency, and improves consistency. Start at 2 mg before high-risk activities.
• Rome IV explicitly includes psychological causes in the classification of functional fecal incontinence — anxiety, depression, trauma history, and post-traumatic stress disorder can contribute through altered rectal sensory thresholds and evacuation dysfunction.

Next steps

Functional Fecal Incontinence confirmed: Establish symptom phenotype (passive vs. urge vs. post-defecatory). Anorectal manometry is the key physiological investigation — assess resting and squeeze pressures, rectal compliance, and rectal sensation threshold. Endoanal ultrasound if sphincter defect is suspected. Treatment by mechanism: (1) Diarrhea-associated: loperamide 2–4 mg before meals/high-risk activities; dietary optimisation (reduced fat, caffeine, insoluble fibre). (2) Passive incontinence (IAS weakness): pelvic floor physiotherapy; biofeedback; topical phenylephrine gel (10%). (3) Urge incontinence (EAS weakness/impaired squeeze): biofeedback with rectal balloon training; sacral nerve stimulation (SNS) if refractory. (4) Rectal hypersensitivity: sacral nerve stimulation; rectal sensory training. (5) All types: anal sphincter exercises; bowel habit regularity; perianal skin care. Sacral nerve stimulation (SNS) is indicated for refractory functional fecal incontinence with intact or minor sphincter defects — success rate 70–80%. Sphincteroplasty is indicated for significant, documented sphincter defect with good muscle tissue. Criteria not met: complete organic workup — neurology referral if neurological cause suspected; colorectal surgery if major structural cause.

Evidence

Bharucha AE, Rao SS, Shin AS. Surgical Interventions and the Use of Device-Aided Therapy for the Treatment of Fecal Incontinence and Defecatory Disorders. Clin Gastroenterol Hepatol. 2017;15(12):1844-1854. Bharucha AE, Dunivan G, Goode PS et al. Epidemiology, pathophysiology, and classification of fecal incontinence: State of the Science Summary for the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) Workshop. Am J Gastroenterol. 2015;110(1):127-136. PMID:25533002. Rome Foundation: Drossman DA (ed). Rome IV: Functional Gastrointestinal Disorders. 4th ed. Rome Foundation, 2016. Paquette IM et al. The American Society of Colon and Rectal Surgeons' Clinical Practice Guideline for the Treatment of Fecal Incontinence. Dis Colon Rectum. 2015;58(7):623-636. PMID:26200676.

References

1. Bharucha AE, Rao SS, Shin AS. Functional Anorectal Disorders. Gastroenterology. 2016;150(6):1430-1442.e4. — link
2. Bharucha AE, Dunivan G, Goode PS et al. Epidemiology, pathophysiology, and classification of fecal incontinence. Am J Gastroenterol. 2015;110(1):127-136. — link
3. Paquette IM, Varma M, Ternent C et al. The American Society of Colon and Rectal Surgeons Clinical Practice Guideline for the Treatment of Fecal Incontinence. Dis Colon Rectum. 2015;58(7):623-636. — link
4. Drossman DA (ed). Rome IV: Functional Gastrointestinal Disorders. 4th ed. Raleigh, NC: Rome Foundation; 2016. — link
5. Thin NN, Horrocks EJ, Hotouras A et al. Systematic review of the clinical effectiveness of neuromodulation in the treatment of faecal incontinence. Br J Surg. 2013;100(11):1430-1447. — link